Icosavax to Participate in the Cowen 42nd Annual Health Care Conference
Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical firm, announced its participation in the Cowen 42nd Annual Health Care Conference, scheduled for March 7-9, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical firm, announced its participation in the Cowen 42nd Annual Health Care Conference, scheduled for March 7-9, 2022. Adam Simpson, CEO, will join an Infectious Disease corporate panel on March 9 at 10:30 a.m. Eastern Time. Interested parties can access the live audio webcast via the Investor Relations section of the Icosavax website, with replays available for 30 days post-event.
The company focuses on innovative virus-like particle technology for vaccine development against respiratory diseases, including candidates targeting RSV, hMPV, and SARS-CoV-2.
Details
News Market Reaction – ICVX
The recorded move for ICVX in the trading session of this news was +4.49%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, March 02, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today announced that the company will participate in the Cowen 42nd Annual Health Care Conference taking place virtually from March 7-9, 2022.
Adam Simpson, Chief Executive Officer of Icosavax, is scheduled to participate in the Infectious Disease corporate panel discussion on Wednesday, March 9, at 10:30 a.m. Eastern Time.
Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.icosavax.com. The webcast replay will be available after the conclusion of the panel discussion for approximately 30 days.
About Icosavax
Icosavax is a biopharmaceutical company leveraging its innovative VLP platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision for combination and pan-respiratory vaccines. Icosavax’s VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which it believes will induce broad, robust, and durable protection against the specific viruses targeted. Icosavax’s pipeline includes vaccine candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and an emerging program in influenza. Icosavax was formed in 2017 to advance the breakthrough VLP technology from the Institute for Protein Design at the University of Washington with the goal to discover, develop, and commercialize vaccines against infectious diseases. Icosavax is located in Seattle.
Media Contact:
Jessica Yingling, Ph.D.
Little Dog Communications Inc.
jessica@litldog.com
+1.858.344.8091
Investor Contact:
Laurence Watts
Gilmartin Group, LLC
laurence@gilmartinir.com
+1.619.916.7620
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.